As part of Biogen’s commitment to continuous improvement and innovation, lmraldi™’s new formulation has been developed to provide an optimised lmraldi™ injection experience for your patients by making an additional adalimumab option available.
lmraldi™’s new low-volume, citrate-free formulation1 is designed to give patients a more comfortable injection experience
- A low injection volume, citrate-free formulation may reduce injection-site pain and increase patient comfort2
- Patients prefer the lmraldi™ pen over the Humira® and Enbrel® MyClic® pens due to reasons such as ease of use, ease of grip, and its button-free initiation mechanism3a
- As of October 2022 lmraldi™ has the longest room-temperature stability of any adalimumab1,5-8
- This means less restrictions on your patients’ lifestyles